Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
5.25
+0.29 (5.92%)
Jun 29, 2026, 1:40 PM EDT - Market open
Cingulate Employees
Cingulate had 14 employees as of December 31, 2025. The number of employees increased by 1 or 7.69% compared to the previous year.
Employees
14
Change (1Y)
1
Growth (1Y)
7.69%
Revenue / Employee
n/a
Profits / Employee
-$1,993,523
Market Cap
70.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 1 | 7.69% |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -2 | -13.33% |
| Dec 31, 2022 | 15 | -1 | -6.25% |
| Dec 31, 2021 | 16 | 4 | 33.33% |
| Sep 30, 2021 | 13 | 1 | 8.33% |
| Jun 30, 2021 | 13 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 139 |
| XBiotech | 87 |
| Acrivon Therapeutics | 76 |
| Seres Therapeutics | 66 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| BeyondSpring | 44 |
| eXoZymes | 32 |
CING News
- 13 days ago - Cingulate issues patent by USPTO for CTx-1301 - TheFly
- 13 days ago - Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - GlobeNewsWire
- 24 days ago - Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - Newsfile Corp
- 25 days ago - Roth sees ‘major silver lining’ in Cingulate complete response letter - TheFly
- 27 days ago - Cingulate issued complete response letter for CTx-1301 from FDA - TheFly
- 27 days ago - US FDA declines to approve Cingulate's ADHD drug - Reuters
- 27 days ago - Cingulate Receives Complete Response Letter from FDA for CTx-1301 - GlobeNewsWire
- 4 weeks ago - Cingulate Proxy statement: Proxy filing - Filings